A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer

• Material Type: 博士論文
• Title: A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer
• Author/Editor: Goji, Takahiro; Kimura, Tetsuo; Miyamoto, Hiroshi; Takehara, Masanori; Kagemoto, Kaizo; Okada, Yasuyuki; Okazaki, Jun; Takaoka, Yoshifumi; Miyamoto, Yoshihiko; Mitsui, Yasuhiro; Matsumoto, Sayo; Sueuchi, Tatsuhisa; Tanaka, Kumiko; Fujino, Yasuteru; Takaoka, Toshi; Kitamura, Shinji; Okamoto, Koichi; Kimura, Masako; Sogabe, Masahiro; Muguruma, Naoki; Okahisa, Toshiya; Sato, Yasuhiro; Sagawa, Tamotsu; Fujikawa, Koji; Sato, Yasushi; Ikushima, Hitoshi; Takayama, Tetsuji
• Author Heading: Goji, Takahiro; Kimura, Tetsuo; Miyamoto, Hiroshi; Takehara, Masanori; Kagemoto, Kaizo; Okada, Yasuyuki; Okazaki, Jun; Takaoka, Yoshifumi; Miyamoto, Yoshihiko; Mitsui, Yasuhiro; Matsumoto, Sayo; Sueuchi, Tatsuhisa; Tanaka, Kumiko; Fujino, Yasuteru; Takaoka, Toshi; Kitamura, Shinji; Okamoto, Koichi; Kimura, Masako; Sogabe, Masahiro; Muguruma, Naoki; Okahisa, Toshiya; Sato, Yasuhiro; Sagawa, Tamotsu; Fujikawa, Koji; Sato, Yasushi; Ikushima, Hitoshi; Takayama, Tetsuji
• Publication, Distribution, etc.: Springer nature
• Publication Date: 2015-07-29
• Publication Date (W3CDTF): 2015-07-29
• Alternative Title: 局所進行膵癌に対するゲムシタビン定速静注及びS-1併用化学放射線療法の第Ⅰ/Ⅱ相試験; FDR-gem plus S-1 with RT for pancreatic cancer
• Periodical title: Cancer Chemotherapy and Pharmacology
• No. or year of volume/issue: 76 3
• Volume: 76
• Issue: 3
• Pages: 615-620
• ISSN (Periodical Title): ISSN : 0344-5704; ISSN : 1432-0843
• Degree grantor/type: 徳島大学
• Date Granted: 2017-03-23
• Dissertation Number: 甲第3028号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: Pancreatic cancer; Chemoradiotherapy; Fixed-dose-rate gemcitabine; S-1; gemcitabine; radiosensitizer
• Target Audience: 一般
• Note (General): Purpose: This study was conducted to identify the maximum-tolerated dose (MTD) of fixed-dose-rate gemcitabine (FDR-gem) administered concurrently with S-1 and radical radiation for locally advanced pancreatic cancer (LAPC) and to provide efficacy and safety data. Methods: Patients with unresectable pancreatic cancer confined to the pancreatic region were treated with FDR-gem (300-400mg/m2, 5mg/m2/min) on days 1, 8, 22, 29 and 60mg/m2 of S-1 orally on days 1-14, 22-35. A total radiation dose of 50.4 Gy (1.8 Gy/day, 28fractions) was delivered concurrently. Results: Twenty-five patients were enrolled; all were evaluable for toxicity assessment. In phase I, eight patients were treated in sequential cohorts of three to five patients per dose level. The MTD was reached at level 2, and dose-limiting toxicities were neutropenia and thrombocytopenia. The recommended doses were 300mg/m2 of gemcitabine and 60mg/m2 of S-1 daily. The overall response rate was 25% and disease control rate (partial response plus stable disease) was 92%. The progression-free survival was 11.0 months. The median overall survival and 1-year survival rate were 16.0 months and 73%, respectively. Conclusion: The combination of FDR-gem and S-1 with radiation is a feasible regimen that shows favorable antitumor activity with an acceptable safety profile in patients with LAPC.
• Format (IMT): application/pdf
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.1007/s00280-015-2835-3
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 徳島大学 : 徳島大学機関リポジトリ

Table of Contents

http://repo.lib.tokushima-u.ac.jp/files/public/11/110046/20170929142602211579/LID201704141008.pdf fulltext

http://repo.lib.tokushima-u.ac.jp/files/public/11/110046/20180308141019248985/k3028_fulltext.pdf fulltext